Invitae Partners with BridgeBio Pharma to Harness Genetic Insights for the Discovery of Rare Disease Therapeutics

1/30/24 7:07:59 AM ET

$BBIO

$NVTA

Biotechnology: Pharmaceutical Preparations

Health Care

Medical Specialities

Health Care

Get the next $BBIO alert in real time by email

Invitae (NYSE:NVTA), a leading medical genetics company, today announced a partnership with BridgeBio Pharma, Inc. (NASDAQ:BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, designed to advance genetics-based drug discovery for rare diseases. The goal of the collaboration is to generate new insights focused on genetic modifiers and the discovery of novel therapeutic targets for rare diseases and other unmet medical needs.

Get the next $BBIO alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$BBIO
$NVTA

Company	Date	Price Target	Rating	Analyst
BridgeBio Pharma Inc. $BBIO	10/16/2024		Sector Outperform	Scotiabank
BridgeBio Pharma Inc. $BBIO	10/3/2024		Perform	Oppenheimer
BridgeBio Pharma Inc. $BBIO	9/4/2024	$46.00	Overweight	Piper Sandler
BridgeBio Pharma Inc. $BBIO	3/21/2024	$45.00	Outperform	Raymond James
BridgeBio Pharma Inc. $BBIO	1/31/2024	$37.00	Market Perform	BMO Capital Markets
BridgeBio Pharma Inc. $BBIO	12/8/2023	$58.00	Overweight	Wells Fargo
BridgeBio Pharma Inc. $BBIO	12/8/2023		Overweight	Wells Fargo
BridgeBio Pharma Inc. $BBIO	11/7/2023	$42.00	Buy	Citigroup

More analyst ratings

$BBIO
$NVTA
Leadership Updates

Live Leadership Updates

BridgeBio Announces Appointment of Thomas Trimarchi, Ph.D., as President and Chief Operating Officer
PALO ALTO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commercial-stage biopharmaceutical company focused on genetic diseases, announced that Thomas Trimarchi, Ph.D., has been appointed President and Chief Operating Officer (COO) of the company. Dr. Trimarchi will assume his new responsibilities effective immediately and will continue to report directly to CEO and founder, Neil Kumar, Ph.D. In this newly created position, Dr. Trimarchi will be responsible for driving operational excellence, strategic planning, and overall business success at BridgeBio. He will lead cross-functional activities to develop a centralized ope
7/23/24 7:30:00 AM ET
$BBIO
Biotechnology: Pharmaceutical Preparations
Health Care
BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipeline
The oversubscribed financing was led by Cormorant Asset Management and co-led by Omega Funds with participation from affiliates of Deerfield Management, GV (Google Ventures), EcoR1 Capital, Wellington Management, Enavate Sciences, Surveyor Capital (a Citadel company), Aisling Capital, Casdin Capital, and Longwood FundThis capital raise provides BBOT with runway to achieve significant clinical inflection points over the next 18-24 months as it progresses multiple assets into the clinic to treat patients with a wide variety of RAS and PI3Kα pathway malignancies PALO ALTO, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commerci
5/2/24 7:00:00 AM ET
$BBIO
Biotechnology: Pharmaceutical Preparations
Health Care
Aranscia Acquires YouScript from Invitae
Pioneering Pharmacogenomics Platform Joins Portfolio of Complementary Precision Medicine Workflow Solutions Aranscia, a global provider of diagnostics software, services, and testing solutions, and Invitae Corporation, a leading medical genetics company, today announced that Aranscia has acquired select assets of the YouScript personalized medication management platform from Invitae Corporation in an all-cash transaction. YouScript is a widely recognized leader in providing actionable, real-time medication risk and pharmacogenomics (PGx) insights that enable healthcare providers and organizations to build, deliver, and scale comprehensive personalized medication management programs. YouSc
11/15/23 4:35:00 PM ET
$NVTA
Medical Specialities
Health Care

$BBIO
$NVTA
Financials

Live finance-specific insights

BridgeBio Announces Durable Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia, and First Participant Consented in ACCEL for Hypochondroplasia
- In Cohort 5 of PROPEL 2 (0.25 mg/kg/day), oral treatment with infigratinib resulted in a statistically significant and sustained increase in annualized height velocity (AHV), with a mean change from baseline of +2.51cm/yr at Month 12, and +2.50 cm/yr at Month 18 (p=0.0015) - At Month 18, there was a statistically significant improvement in body proportionality (p-value of 0.001). The mean upper to lower body segment ratio was 1.88 at Month 18, as compared to 2.02 at baseline - Infigratinib continues to be well-tolerated as a single daily oral therapy with no adverse events (AEs) assessed as treatment-related in any participant in Cohort 5 - PROPEL 3, the global Phase 3 registrational s
6/4/24 7:30:00 AM ET
$BBIO
Biotechnology: Pharmaceutical Preparations
Health Care
Additional Data Showing Acoramidis Increases Serum Transthyretin Which is Associated with Improved Cardiovascular Outcomes Presented at ISA from BridgeBio Pharma's Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
- Acoramidis treatment resulted in increased serum transthyretin (TTR) levels by Day 28 that were sustained and were correlated with a reduced risk of all-cause mortality (ACM), cardiovascular mortality (CVM), and cardiovascular-related hospitalization (CVH) in ATTR-CM participants through month 30 - Acoramidis treatment resulted in a significant improvement in the composite endpoint of CVM and CVH in ATTR-CM participants, with benefit evident as early as Month 3 - In ATTRibute-CM, participants with at least one CVH had a significantly higher risk of mortality, highlighting the need for ATTR-CM treatments that reduce risk of CVH - BridgeBio also shared the rationale and design of ACT-EAR
5/29/24 4:01:00 PM ET
$BBIO
Biotechnology: Pharmaceutical Preparations
Health Care
BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the 2024 ISA Meeting
- BridgeBio to host investor call on Wednesday, May 29, 2024 at 5:30 pm ET, with presentations from Mathew Maurer, M.D. of Columbia University Irving Medical Center, U.S. and Ahmad Masri, M.D., M.S. of Oregon Health & Science University, U.S. PALO ALTO, Calif., May 24, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced today that 12 oral and moderated poster presentations will be shared at the 2024 International Symposium on Amyloidosis (ISA), taking place in Rochester, Minnesota on May 26 - 30, 2024. BridgeBio will also host an investor call on May 2
5/24/24 7:30:00 AM ET
$BBIO
Biotechnology: Pharmaceutical Preparations
Health Care

$BBIO
$NVTA
Press Releases

Fastest customizable press release news feed in the world

Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months
- Acoramidis demonstrated the earliest known time to separation in cardiovascular outcomes in the ATTRibute-CM study (3 months), with statistically significant risk reduction of 36% on All-Cause Mortality (ACM) alone at Month 36 within the Open Label Extension - The continued curve separation of the composite endpoint of ACM and recurrent cardiovascular-related hospitalizations (CVH) emphasizes the importance of early intervention resulting in early and sustained clinical benefits, with acoramidis demonstrating 46% (p<0.0001) and 48% (p<0.0001) reductions in the composite endpoint of ACM and recurrent CVH at Months 36 and 42, respectively - The preliminary results from this ongoing OLE st
11/18/24 11:15:00 AM ET
$BBIO
Biotechnology: Pharmaceutical Preparations
Health Care
BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia
- In Cohort 5 of PROPEL 2, daily oral treatment of infigratinib at 0.25mg/kg resulted in statistically significant and sustained increases in annualized height velocity (AHV), with a mean change from baseline of +2.50cm/year at Month 18 (P=0.001) - Data also presented at European Society of Paediatric Endocrinology on November 18th at 10 am GMT - To date, infigratinib has received Breakthrough Designation from the U.S. Food and Drug Administration for achondroplasia, as well as Orphan Drug Designation, Fast Track Designation, and Rare Pediatric Disease Designation - PROPEL 3, the global Phase 3 registrational study of infigratinib in achondroplasia, continues to enroll on schedule, with e
11/18/24 5:30:00 AM ET
$BBIO
Biotechnology: Pharmaceutical Preparations
Health Care
BridgeBio Pharma Reports Third Quarter 2024 Financial Results and Business Update
- Patients on acoramidis, a near complete (≥90%) TTR stabilizer in clinical development, lived longer and better as shown in the ATTRibute-CM study. This is the only Phase 3 study of an ATTR-CM disease-modifying treatment to demonstrate improvement in hard clinical outcomes in the combined assessment of CVH and ACM to this degree, this quickly - BridgeBio's late-stage pipeline continues to rapidly progress with three Phase 3 readouts expected in 2025. Program highlights from this quarter include: - CALIBRATE, the Phase 3 clinical trial of encaleret in ADH1, completed screening - FORTIFY, the Phase 3 clinical trial for LGMD2I/R9, completed enrollment - The FDA granted Break
11/12/24 7:30:00 AM ET
$BBIO
Biotechnology: Pharmaceutical Preparations
Health Care

Invitae Partners with BridgeBio Pharma to Harness Genetic Insights for the Discovery of Rare Disease Therapeutics

Chat with this insight

Recent Analyst Ratings for $BBIO$NVTA

$BBIO$NVTA Leadership Updates

Live Leadership Updates

BridgeBio Announces Appointment of Thomas Trimarchi, Ph.D., as President and Chief Operating Officer

BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipeline

Aranscia Acquires YouScript from Invitae

$BBIO$NVTA Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13D/A filed by BridgeBio Pharma Inc.

Amendment: SEC Form SC 13D/A filed by BridgeBio Pharma Inc.

Amendment: SEC Form SC 13D/A filed by BridgeBio Pharma Inc.

$BBIO$NVTA SEC Filings

SEC Form 144 filed by BridgeBio Pharma Inc.

BridgeBio Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

SEC Form 144 filed by BridgeBio Pharma Inc.

$BBIO$NVTA Financials

Live finance-specific insights

BridgeBio Announces Durable Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia, and First Participant Consented in ACCEL for Hypochondroplasia

Additional Data Showing Acoramidis Increases Serum Transthyretin Which is Associated with Improved Cardiovascular Outcomes Presented at ISA from BridgeBio Pharma's Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the 2024 ISA Meeting

$BBIO$NVTA Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Scotiabank initiated coverage on BridgeBio Pharma

Oppenheimer initiated coverage on BridgeBio Pharma

Piper Sandler initiated coverage on BridgeBio Pharma with a new price target

$BBIO$NVTA Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

$BBIO$NVTA Market Insights

Live Market Insights

Chief Executive Officer Kumar Neil sold $613,826 worth of shares (27,389 units at $22.41), decreasing direct ownership by 0.56% to 4,897,443 units (SEC Form 4)

Secretary, Treasurer & CFO Stephenson Brian C sold $93,137 worth of shares (4,156 units at $22.41), decreasing direct ownership by 4% to 93,758 units (SEC Form 4)

Chief Executive Officer Kumar Neil converted options into 55,537 shares and covered exercise/tax liability with 28,148 shares, increasing direct ownership by 0.56% to 4,924,832 units (SEC Form 4)

BridgeBio Appoints Thomas Trimarchi As President And Chief Operating Officer Effective Immediately

Cantor Fitzgerald Reiterates Overweight on BridgeBio Pharma, Maintains $70 Price Target

B of A Securities Maintains Buy on BridgeBio Pharma, Lowers Price Target to $42

$BBIO$NVTA Press Releases

Fastest customizable press release news feed in the world

Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months

BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia

BridgeBio Pharma Reports Third Quarter 2024 Financial Results and Business Update

$BBIO$NVTA Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Valantine Hannah bought $44,476 worth of shares (3,433 units at $12.96) (SEC Form 4)

Recent Analyst Ratings for
$BBIO
$NVTA

$BBIO
$NVTA
Leadership Updates

$BBIO
$NVTA
Large Ownership Changes

$BBIO
$NVTA
SEC Filings

$BBIO
$NVTA
Financials

$BBIO
$NVTA
Analyst Ratings

$BBIO
$NVTA
Insider Trading

$BBIO
$NVTA
Market Insights

$BBIO
$NVTA
Press Releases

$BBIO
$NVTA
Insider Purchases